We scan new podcasts and send you the top 5 insights daily.
Alex says one-and-done vaccines such as RSV, shingles and pneumonia are best given before a bispecific or at least a year after, when immune response is likely better. Flu and COVID vaccines are still recommended, but she spaces them six to eight weeks before PET to avoid vaccine-related adenopathy.
Manali says there is no data for prophylactic tocilizumab with lymphoma CD20 bispecifics, unlike myeloma, so she does not use it. Patients instead receive PJP and HSV prophylaxis and have IgG checked, with IVIG for IgG below 400 or recurrent infections. That prophylaxis package differs from CAR T.
While the gut instinct is that patients prefer daily pills over injections, this preference flips when the injection is highly infrequent. For chronic conditions, a quarterly shot (four per year) is often viewed as more convenient and favorable by patients than the burden of a daily oral medication, challenging conventional wisdom on administration routes.
Because bispecific antibody regimens are administered over numerous cycles (8 to 12 cycles or more), normal B cells are continually suppressed and cannot recover. This induces severe, persistent hypogammaglobulinemia. All patients receiving B-cell bispecifics require acyclovir prophylaxis for shingles, PJP prophylaxis if receiving steroids, and regular IVIG replacement therapy to avoid chronic sinus and upper respiratory tract infections.
A newborn's immune system is intentionally weak for the first six months. This is a protective mechanism to prevent it from attacking the child's own rapidly developing tissues, which could be mistaken for foreign invaders. This is why some childhood vaccinations are delayed until after this period.
Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.
To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.
For patients who previously received immunotherapy (IO), a recurrence more than 12 months after completing treatment makes re-challenging with an IO agent a reasonable option. The likelihood of benefit is lower if the recurrence is within 6-12 months and minimal if under 6 months.
The U.S. recommends 72 vaccine doses for children from birth to 18, a number significantly higher than 20 other developed nations. To combat falling vaccination rates and rebuild trust, the FDA is now highlighting a "core essential" list of approximately 38 vaccines.
Nurses can better anticipate and educate patients about immunotherapy side effects by understanding their typical timeline. Skin and GI issues often appear within the first month, while thyroid or other endocrine problems may not manifest for two months or more.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.